Loading patent…
AssigneeSolarea Bio, Inc.
InventorsEric Michael Schott, Gerardo V. Toledo, Maria Juliana Soto-Giron, Alicia Eve Ballok, Ryan Green, Mark Charbonneau
Estimating the term…
This disclosure provides for compositions (e.g., pharmaceutical compositions, dietary supplements, medical foods and food stuff), comprising combinations of live microbe populations for the treatment and/or prevention of immune system disorders and conditions related to inflammation, including both pathogen assisted conditions and conditions that are independent of pathogens. Included with the present disclosure are methods for use of the compositions, and methods for selecting microbial entities to formulate the compositions of the disclosure.
A composition formulated for oral administration comprising a combination of at least two heterologous microbes selected from Lactobacillus harbinensis, Lactobacillus brevis, Lactococcus lactis, and Bacillus velezensis, wherein the heterologous microbes are formulated as a synthetic microbial consortium comprising about 1.0×108 to about 1.0×1012 CFU of each of the heterologous microbes, and wherein at least one of the heterologous microbes comprises a 16S rRNA sequence having at least 97%, at least 98%, at least 98.5%, at least 99%, or at least 100% identity to any one of SEQ ID NOs:
A composition formulated for oral administration comprising a combination of at least two heterologous microbes selected from Lactobacillus brevis, Lactococcus lactis, and Bacillus velezensis, wherein the heterologous microbes are formulated as a synthetic microbial consortium comprising about 1.0×108 to about 1.0×1012 CFU of each of the heterologous microbes, and wherein at least one of the heterologous microbes comprises a 16S rRNA sequence having at least 97%, at least 98%, at least 98.5%, at least 99%, or at least 100% identity to any one of SEQ ID NOs:
A composition formulated for oral administration comprising a combination of at least two heterologous microbes comprising Lactobacillus brevis and Lactococcus lactis, wherein the heterologous microbes are formulated as a synthetic microbial consortium comprising about 1.0×108 to about 1.0×1012 CFU of each of the heterologous microbes, wherein at least one of the heterologous microbes comprises a 16S rRNA sequence having at least 97%, at least 98%, at least 98.5%, at least 99%, or at least 100% identity to any one of SEQ ID NOs:
Dependencies are inferred from the claim text.